Relmada Therapeutics, Inc.
RLMD
$7.49
$0.040.54%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
5/13/2026
-
MarketBeat
5/13/2026
-
Seeking Alpha: Transcripts
5/13/2026
-
TipRanks Financial Blog
5/12/2026
-
Benzinga
5/12/2026
-
Globe Newswire
5/9/2026
-
MarketBeat
5/6/2026
-
MarketBeat
5/6/2026
-
Globe Newswire
5/5/2026
-
Globe Newswire
5/4/2026
-
MarketBeat
5/2/2026
-
Tickeron - Stocks
4/29/2026
-
Tickeron - Stocks
4/18/2026
-
Tickeron - Stocks
4/17/2026
-
Tickeron - Technical Analysis
4/17/2026
-
TipRanks Financial Blog
4/16/2026
-
MarketBeat
4/13/2026
-
MarketBeat
4/13/2026
-
Zacks Investment Research
4/11/2026
-
Tickeron - Technical Analysis
4/10/2026
-
Tickeron - Technical Analysis
4/10/2026
-
Tickeron - Technical Analysis
4/9/2026
-
MarketBeat
4/8/2026
-
Tickeron - Technical Analysis
4/8/2026
-
TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, March 19, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of May 11 and 15 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
786 629 1376
Address
2222 Ponce de Leon Blvd.
Coral Gables, FL 33134
Coral Gables, FL 33134
Country
Year Founded
Business Description
Sector
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation...
more